Over the past decade we have seen a gradual increase in reports giving more support to the hypothesis that mildly or moderately increased values of serum prolactin have a role in the pathogenesis and clinical activity of systemic lupus erythematosus (SLE). Jara et al summed up this information in an article published in a special edition of the international journal Lupus.1 “Idiopathic hyperprolactinemia” (hyperprolactin) has been confirmed under a variety of conditions by several authors, including us,2 in 20–30% of patients with SLE investigated; nevertheless, opinion continues to vary about its connection with greatly increased clinical activity of the disease.3,4

Prolactin is a hormone with a very wide range of action, and its effect on the immune response has been proved in both animal experiments3 and in humans.6 It is also one of the stress hormones, and the physiological 24 hour curve of its serum concentrations is similar to that of the growth hormone, a near relation, but not to those of the hormones along the line connecting the hypothalamus-pituitary-adrenocortex.

In our first experiments designed to reproduce the study of hyperprolactin in patients with SLE or even rheumatoid arthritis (RA), we took account of the fact, emphasised by endocrinologists, that prolactin as a stress hormone is released in repeated pulses rather than continually; this is true at least, for the prolactin of pituitary origin, though not prolactin secreted in lymphoid paracrine tissue.7 The secretion of prolactin in the adenohypophysis is controlled indirectly by suppressing the inhibitory factor, which is synthesised and secreted in lymphoid paracrine tissue.

In repeated pulses rather than continually; this is true at least, for the prolactin of pituitary origin, though not prolactin secreted in lymphoid paracrine tissue.7 The secretion of prolactin in the adenohypophysis is controlled indirectly by suppressing the inhibitory factor, which is synthesised and secreted in lymphoid paracrine tissue.

Figure 1 Association of raised prolactin with diagnosis (number of observations). Results are shown for the three groups investigated: healthy controls, patients with SLE, and RA. (A) Percentage of subjects with increased serum prolactin levels in all three blood samples; only these subjects meet the condition of increased serum prolactin and, consequently, the presence of “idiopathic hyperprolactinaemia”. (B) Percentage of subjects with increased serum prolactin levels found in only one or two blood samples. An increase in only the first or in the first and second samples is taken as a sign of transitory reaction to stress caused by introducing a canula into the vein. (C) Percentage of subjects with normal serum prolactin levels found in all three blood samples; the between-group difference in the distribution of hyperprolactinaemia between the patients with SLE and RA and healthy controls is highly significant (p<0.009).

Serum prolactin stress values in patients with systemic lupus erythematosus

C Dostál, L Moszkorzová, L Musilová, Z Lacinová, J Marek, J Zvárová


score activity (fig 1). Next, 23 patients (that is, 69 serum samples) with RA were investigated, who were also in different stages and activity of the disease. Twenty-eight healthy subjects (that is, 84 serum samples), matched for age and sex with the SLE group, were investigated as controls. All patients and healthy controls receiving drugs known to influence prolactin secretion were excluded from the investigation.

The serum concentrations of prolactin were measured in duplicate by immunoradiometric assay (Immunotech, Prague). Prolactin levels gradually declined in successive serum samples (table 1). The differences in prolactin levels between samples 1 and 3 were highly significant for patients with SLE and RA. The statistical significance of this difference (between samples 1 and 3) was tested using the Wilcoxon matched pairs test in patients with SLE and RA, and healthy controls. The presence of hyperprolactin was rated as mild (200–350 mIU/l for men, 450–600 mIU/l for women), moderate (350–750 mIU/l for men, 600–1000 mIU/l for women), and high (>750 for men, >1000 for women). Serum hyperprolactin was found in 32/79 (41%) patients with SLE, of whom 20 (63%) had the mild type, nine (28%) the moderate, and three (9%) the high level type. In RA, serum hyperprolactin was found in 11/28 (39%) patients, of whom eight (73%) had the mild type, three (27%) the moderate form, and none had the high level type. In healthy controls, serum hyperprolactin was found in 5/28 (18%) subjects—all with the mild form. These figures apply only when increased concentrations of serum hyperprolactin were found in all three samples. If increased serum prolactin is found in only one or two samples the findings may easily be misinterpreted as seen from figure 1. Thus for the 28 healthy subjects investigated raised levels were
found in all three serum samples in five (18%); in one or two samples in four (14%); and normal levels were found in 19 (68%). Similarly, for the 79 patients with SLE raised levels were found in all three serum samples in 29 (37%); in one or two samples in 19 (24%); and normal levels were found in five (6%). Finally, for the 23 patients with RA raised levels were found in all three serum samples in eight (35%); in one or two samples in 19 (24%); and normal levels were found in 31 (68%).

Using Pearson’s χ² test for contingency table, we determined significant difference (p<0.01) in the distribution of normal or raised serum prolactin levels when three blood samples were taken or when one or two samples only were taken, between patients with SLE/RA and healthy controls. The possible disregulation due to the presence of a systemic autoimmune disease requires further study.

ACKNOWLEDGEMENT

This study was supported by the Internal Grant Agency of Ministry of Health of the Czech Republic No NK 5370–3/99.

Authors’ affiliations
C Dostál, L Moszkorzová, L Musilová, Institute of Rheumatology, Na Slupi 4, Prague 2, 128 30 Czech Republic
Z Lacinová, J Marek, 3rd Medical Department, 1st Medical Faculty, Charles University, Prague 2, Czech Republic
J Zvárová, EuroMISE Centre, Charles University and Ac Sciences, Prague 2, Czech Republic

Correspondence to: Professor C Dostál; dost@revma.cz

Accepted 8 October 2002

REFERENCES

Table 1 Serum prolactin values in patients with SLE, RA, and in healthy controls (in three successively taken samples)

<table>
<thead>
<tr>
<th>Serum prolactin level (mIU/l)</th>
<th>SLE (n=79)</th>
<th>RA (n=23)</th>
<th>Healthy (n=28)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>Mean</td>
<td>Mean</td>
</tr>
<tr>
<td>1st Sample</td>
<td>700.72</td>
<td>516.13</td>
<td>227.93</td>
</tr>
<tr>
<td>2nd Sample</td>
<td>618.79</td>
<td>417.00</td>
<td>212.36</td>
</tr>
<tr>
<td>3rd Sample</td>
<td>572.17</td>
<td>370.75</td>
<td>191.00</td>
</tr>
<tr>
<td>Difference between 1st and 3rd sample (p value)</td>
<td>&lt; 0.001</td>
<td>0.08 NS</td>
<td>&lt;0.007</td>
</tr>
<tr>
<td>Q3 – Q1</td>
<td>93 – 92</td>
<td>126 – 78</td>
<td>152 – 79</td>
</tr>
<tr>
<td>95% CI</td>
<td>210 to 420</td>
<td>133 to 279</td>
<td>236 to 306</td>
</tr>
<tr>
<td>SD</td>
<td>84.45</td>
<td>134.96</td>
<td>134.96</td>
</tr>
</tbody>
</table>

Q3 – Q1, 75th quartile – 25th quartile.
Cyclosporin treatment in psoriatic arthritis: a cause of severe leg pain
C A Lawson, A Fraser, D J Veale, P Emery

CASE REPORT
We describe a case of severe leg pain in a young woman receiving cyclosporin. She was referred to our department at the age of 18 with psoriatic arthritis that had started five years previously. Owing to intolerance of sulfasalazine she had been receiving cyclosporin 100 mg twice a day (3.3 mg/kg) for the preceding seven months before review in combination with methotrexate. Two weeks after referral to our department she began to develop non-specific thigh pains, and the possibility of myalgia due to cyclosporin was suggested. Her dose was reduced but with no change in symptoms. At this point she was taking regular opioids in an attempt to ease her symptoms.

She was admitted for further assessment. On questioning, her leg pain consisted of a burning sensation radiating from her thighs to her ankles, and was intermittent every one to two days lasting several hours at a time. She found relief from lying flat and applying local heat, but only minimal benefit from analgesia such as co-codamol. She had difficulty walking when pain was present and her sleep was disturbed. Examination showed the only abnormalities to be psoriatic plaques, nail pitting, and onycholysis. In particular, examination of the neurological and arterial systems was normal. Initial investigations included urea, creatinine, and electrolytes, a full blood count, liver function tests, C reactive protein, plasma viscosity, rheumatoid factor, antinuclear antibodies, creatine kinase, thyroid function tests, glucose, calcium, vitamin B12, folate, serum electrophoresis, urinary porphyrins, nerve conduction studies, and electromyography, all of which were normal. A measured cyclosporin level was at the lower limit of the therapeutic range.

Trials with analgesia showed that only morphine sulphate eased the severe episodes of pain. The possibility of her symptoms representing a “bone pain syndrome” secondary to cyclosporin was suggested, and her cyclosporin was stopped with continuation of methotrexate. At review two weeks later her pain had completely resolved, and had done so within 48 hours of stopping treatment. In view of this very dramatic response to cyclosporin withdrawal, the description of her symptoms, and the lack of abnormal examination and investigation findings, we felt that this represented “cyclosporin induced leg pain”.

DISCUSSION
There are several reports of this syndrome in patients with a renal transplant who are taking cyclosporin. Among the first was in 1994, describing 15 patients with a renal transplant who presented with severe bone pain that resolved with calcium channel blockade. More recently, a case of leg pain in a patient with Crohn’s disease receiving cyclosporin treatment was reported. The published reports describe the pain characteristically as a bilateral deep aching sensation of acute onset, and episodic lasting several hours at a time. Reports include pain in the knees, ankles, wrists, shoulders, and thighs. Patients often feel worse at night or when lying flat. Pain severity can be linked to higher cyclosporin levels, and reducing the dose may alleviate symptoms. Examination is normal and there are no consistent blood or radiological abnormalities. It has been noted that other side effects of cyclosporin such as hypertension are present in 75% of patients with this type of pain, compared with 34% of asymptomatic patients despite the same mean cyclosporin levels.

Calcium channel blockade appears to be an effective treatment, with a prospective study showing that almost all patients gained complete relief with nifedipine. In our patient it was felt preferable to stop cyclosporin, as her psoriatic arthritis was well controlled and she was continuing to receive methotrexate. Non-steroidal anti-inflammatory drugs and weak opioids have consistently been found to be ineffective. Suggested pathophysiological mechanisms of pain include vasoconstriction of bone vasculature, and interosseous hypertension as seen in sickle cell crisis. Of note is that an acute bone pain syndrome has also been documented in patients with a renal transplant taking tacrolimus.

This syndrome is rare but well documented in patients with a transplant. Many rheumatologists are not aware of this uncommon side effect, and, if undetected, it can lead to the use of potent analgesia in an attempt to alleviate symptoms. Cyclosporin is widely used in rheumatological practice, and this is a potentially treatable side effect if the cause is recognised.

Authors’ affiliations
C A Lawson, A Fraser, D J Veale, P Emery, Department of Rheumatology and Rehabilitation, 36 Clarendon Road, Leeds LS2 9NZ, UK

Correspondence to: Dr C A Lawson, Molecular Medicine Unit, Clinical Sciences Building, St James’s University Hospital, Leeds LS9 7TF, UK; medcl@leeds.ac.uk

Accepted 26 August 2002

REFERENCES

www.annrheumdis.com
Anti-tumour necrosis factor treatment in a patient with anorexia nervosa and juvenile idiopathic arthritis

J Barber, T Sheeran, D Mulherin

Tumour necrosis factor α (TNFα) is believed to have a pivotal role in the pathogenesis of many forms of inflammatory arthritis, and anti-TNFα therapies are now licensed and recommended for the treatment of refractory rheumatoid arthritis and juvenile idiopathic arthritis (JIA). An important role for TNFα in the pathophysiology of anorexia nervosa has also been postulated, although authors differ on the precise mechanisms underlying its role. Some authors have suggested that TNFα may be mediating a stress response, whereas others have proposed that raised levels of TNFα in these patients may be secondary to anorexia rather than a cause. Although the role of anti-TNFα therapies in the management of inflammatory arthritis is well recognised, we are not aware of experience with the use of anti-TNFα treatment in the management of anorexia nervosa. We describe the effect of such treatment prescribed to a woman with refractory JIA and anorexia nervosa.

CASE REPORT
A 28 year old woman with JIA had a disease activity score of 6.68 despite continuing treatment with weekly methotrexate, 10 mg orally. She originally presented to rheumatology care at age 14 years with a nine year history of pain, swelling, and stiffness of the small joints of the hands, wrists, temporomandibular joints, and feet, leading to significant deformity and disability. At that time, her height (151 cm) was on the 50th centile and her weight (30 kg) on the 3rd centile. Family habitus was described as thin. Rheumatoid factor was positive, antinuclear antibody was negative, the C reactive protein was raised (36 mg/l), and an ophthalmological review was normal. Intensive physiotherapy and non-steroidal treatment were instituted.

Her arthritis remained well controlled over the next two years. She gained 5 cm in height but only 1.8 kg in weight, and was noted to eat very little but denied drug or laxative abuse or self induced vomiting. The psychiatric service diagnosed a somewhat unusual presentation of anorexia nervosa with eating phobia and a feeling of being unattractive but at the same time a desire to be heavier. Recent stresses and exacerbation of her arthropathy alone was not the exclusive cause of her anorexia nervosa, it is clearly possible that some of her anorexia stemmed from her underlying inflammatory joint disease: it is impossible to separate these two processes. However, she exhibited abnormal eating behaviour even at times when her arthritis was clinically quiescent, suggesting that her arthropathy alone was not the exclusive cause of her arthritis. Her preliminary response to infliximab raises the intriguing possibility of a new treatment for the potentially life threatening disorder of anorexia nervosa. This clearly warrants further evaluation.

DISCUSSION
Anorexia nervosa is a severe eating behaviour disorder, characterised by weight loss below 85% of the expected body weight, amenorrhoea, and a distorted body image associated with significant morbidity and mortality. It can be distinguished from the constitutional weight loss seen in inflammatory arthropathies by the associated behavioural and perceptual changes relating to food and body image. Clearly, other important causes of weight loss in these patients include occult infection and malignancy or simply the anorexia related to nauseating treatment. TNFα was originally described as “cachexin”, and severe inflammatory arthritis is known to be associated with both cachexia and raised TNFα. TNFα has also been postulated to play an important part in the development of anorexia nervosa. Profound anorexia and pathological weight loss were certainly major features of this patient’s disease. Although she satisfied criteria for a diagnosis of anorexia nervosa, it is clearly possible that some of her anorexia stemmed from her underlying inflammatory joint disease: it is impossible to separate these two processes. However, she exhibited abnormal eating behaviour even at times when her arthritis was clinically quiescent, suggesting that her arthropathy alone was not the exclusive cause of her arthritis. Her preliminary response to infliximab raises the intriguing possibility of a new treatment for the potentially life threatening disorder of anorexia nervosa. This clearly warrants further evaluation.

REFERENCES

J Barber, T Sheeran, D Mulherin, Department of Rheumatology, Cannock Chase Hospital, Brunswick Road, Cannock, WS11 2XY, UK

Correspondence to: Dr D Mulherin; diarmuid.mulherin@msgh-tr.wmids.nhs.uk

Accepted 7 October 2002
Transient joint effusion: a forgotten side effect of high dose corticosteroid treatment

F Schiavon

Pulse therapy with high doses of corticosteroids, although generally well tolerated, is associated with a variety of side effects, sometimes life threatening but, more often, mild. Among these, joint manifestations are only rarely encountered. Patients sometimes feel transient arthralgias, but the development of synovial effusion is exceptionally reported.

We described the case of a woman with systemic lupus erythematosus (SLE) and nephritis who developed a transient bilateral knee synovial effusion during pulse therapy with a high dose of corticosteroids.

CASE REPORT

A 62 year old woman was admitted to our division because of SLE with nephritis. Eight months before the admission, in April 2000, she developed arthritis in the last four toes of the left foot. She was treated with non-steroidal anti-inflammatory drugs, with complete remission. Serological findings showed a raised erythrocyte sedimentation rate (ESR) of 52 mm/1st h, normal C reactive protein, and a decrease in total protein and albumin. Three months later, laboratory features showed an increase in ESR (62 mm/1st h), normal C reactive protein, and a decrease in total protein and albumin. Three months later, (ESR) of 52 mm/1st h, normal C reactive protein, and a decrease in total protein and albumin.

At admission we did not observe any arthritis. On the evening of the second day of pulse steroid therapy, after a short walk, she complained of pain and flexion discomfort to both knees, which a physical examination showed were swollen. Thus, an arthrocentesis was performed with aspiration of synovial fluid (5 ml from the right and 6 ml from the left knee). Synovial fluid analysis showed a colourless fluid, with high viscosity and excellent mucin clot formation (fig 1). A leucocyte count disclosed only 1 mononucleate cell/mm³ in the right knee synovial fluid and no cells in the left. No crystals were identified by light or compensated polarised microscopy. Inflammatory laboratory measurements carried out simultaneously were unchanged. Radiographs of the affected joints showed normal aspects. Effusion resolved with arthrocentesis and did not recur during admission to hospital.

DISCUSSION

A transient non-inflammatory joint effusion was described for the first time by Woods et al. in a patient treated with high dose corticosteroids for the management of renal transplantation, but the characteristics of this effusion were not reported. In other cases of patients treated for renal transplant rejection or lupus nephritis in whom analysis was performed, the synovial fluid was a light yellow or colourless fluid with normal viscosity, low leucocyte count, and lymphocyte or monocyte predominance.1,2 MacFarlane et al. studied the relation between corticosteroid treatment and effusion in patients treated for renal transplantation, by joint radiography, bone scan, and synovial biopsy.3 Because these examinations were always normal, it was postulated that the effusion might result from steroid induced transudation of fluid across synovial capillary walls. A transient synovial fluid knee effusion with the same characteristics was also noted by Lally in 28.3% of patients with chronic obstructive pulmonary disease treated with high dose corticosteroids or during withdrawal from such treatment.4

References

We agree with these authors that the small volume of synovial fluid, the low leucocyte counts, the rapidity of accumulation, and the transient nature of the effusion support a pathogenic mechanism related to fluid shifts across the synovial vasculature. Although glucocorticoids are known to exert a membrane stabilising effect, our patient’s fluid lost its own characteristics (colour, cells, chemical properties) and became similar to plasma as if it had been subjected to increased synovial capillary intravascular pressure. Synovial tissue permeability is markedly affected by increased vascular forces, which alter filtration pressure and synovial fluid production. Bertone et al showed, in an animal study, an increase in trans-synovial fluid flow associated with an increase in arterial and venous pressure.” Raised arterial pressure, which is a side effect of high dose corticosteroid treatment, and low onotic pressure due to a low protein plasma concentration in a nephrotic patient, can increase the trans-synovial fluid flow at a lower arterial pressure than normal. This rare side effect of high dose corticosteroid treatment should not be forgotten.

Effects of interferon α treatment on the clinical course of refractory Behçet’s disease: an open study

M Çalgünéri, M A Öztürk, I Ertenli, S Kiraz, Ş Apraş, Z Özbalkan

Interferon α (IFNα) has recently been introduced in the treatment of uveitis, mucocutaneous lesions, and arthritis of Behçet’s disease (BD). To our knowledge, there is currently no clinical trial which has evaluated the efficacy of IFNα treatment in the vascular or neurological involvement in BD. In this open study we evaluated the efficacy, toxicity, and tolerability of IFNα in the management of BD with ocular, articular, vascular, or neurological manifestations which had previously been unsuccessfully treated conventionally.

PATIENTS AND METHODS

A total of 29 patients (17 men, 12 women; mean age 33.2 months, range 16–51) who were resistant to conventional treatments were treated with systemic IFNα. Previous conventional treatments had been colchicine, aspirin, and penicillin plus sulfasalazine for patients with arthritis; or colchicine, aspirin, and penicillin plus steroids and/or immunosuppressive agents, azathioprine, cyclosporin A, or cyclophosphamide for ocular, vascular, and/or neurological involvement which had previously been unsuccessfully treated conventionally.

Four patients had parenchymal neurological complications which were diagnosed with physical examination and magnetic resonance imaging.

All patients were treated with colchicine 1.5 mg/day orally in three divided doses, aspirin 80 mg/day, and intramuscular benzathine penicillin 1.2 million units every three weeks. Thrombotic occlusions were also treated with anticoagulant agents. Cyclophosphamide was continued together with IFNα in one patient with neurological and vascular disease.

The patients were followed up regularly every 3–6 months. The IFNα dose was 5 million units subcutaneously three times a week, and this was tapered to 3 million units three times a week after 6–9 months as clinical response was achieved. The dose intervals were then gradually increased. The dose of IFNα was increased to 10 million units in one patient because of a lack of response.

Data were evaluated according to the following criteria: complete remission, disappearance of all manifestations during treatment; partial remission, >50% decrease in the number, severity, duration, and/or frequency of recurrence of the lesions; stable disease, <50% change in the manifestations; and progressive disease, >50% deterioration of existing manifestations or and the development of new ones.

The visual acuity of two patients had deteriorated severely before they were admitted to our clinic. The IFNα treatment prevented new relapses, and, moreover, after the treatment both patients regained a satisfactory visual acuity which was sufficient for the maintenance of daily activities. Another patient had had intractable ascites due to the organised thrombus in the superior and inferior caval, iliac, and femoral veins. Anticoagulation plus IFNα reduced the amount of ascitic fluid without additional vascular event and improved the general clinical condition of the patient. Those three patients were classified as “remission with sequelae.”

Authors’ affiliations
F Schiavon, Division of Rheumatology, Via Giustiniani 2, 35142 Padova, Italy

Correspondence to Professor F Schiavon, f.schiavon@unipd.it

Accepted 8 August 2002

REFERENCES
RESULTS
The mean duration of IFNα treatment was 22.2 months (range 5–72). The overall response rate was 96% (24/25). Table 1 shows the response rates for the distinct forms of clinical manifestations.

Flu-like symptoms were recorded in eight patients. Serum transaminase levels were reversibly raised in two patients. Although no patient had to discontinue IFNα, the dose was reduced to 3 million units three times a week in one patient because of intolerance.

DISCUSSION
IFNα has previously been given in the treatment of BD with mucocutaneous, articular, and/or ophthalmological manifestations.1,2 Zouboulis and Orfanos extensively reviewed 144 patients with BD who were treated with IFNα.3 Seventy four per cent (92/124) of these patients with mucocutaneous manifestations, 95% (37/39) with uveitis, and 93% (51/55) with arthropathy/arthritis showed a partial or complete response. We found similar response rates for uveitis (16/17, 94%) and arthritis (11/11, 100%).

Although the therapeutic potential of IFNα in BD with vascular or neurological involvement has not been previously investigated, there are some anecdotal reports. In one study treatment with IFNα resulted in complete remission of ocular vasculitis with reperfusion of most of the occluded vessels.2 One patient with BD with gastrointestinal vasculitis4 and two patients with superficial thrombophlebitis improved after IFNα treatment.4,5 Two patients with neuro-BD were reported to be responsive to treatment with IFNα.4 In our study, IFNα produced remission in all patients with neurological or vascular disease (table 1), and, moreover, no recurrence or major toxicity was seen during the long term follow up.

Table 1 Response rates for the distinct forms of clinical manifestations in our patients with Behçet’s disease. Results are shown as No (%) 

<table>
<thead>
<tr>
<th>Type of clinical manifestation</th>
<th>Complete remission</th>
<th>Remission with sequela</th>
<th>Partial response</th>
<th>Progressive disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uveitis</td>
<td>13/17 (76)</td>
<td>2/17 (12)</td>
<td>1/17 (6)</td>
<td>1/17 (6)</td>
</tr>
<tr>
<td>Arthritis</td>
<td>11/11 (100)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vascular disease</td>
<td>9/10 (90)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neurological disease</td>
<td>4/4 (100)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

There is no consensus on the dose of IFNα which should be used for the treatment of BD. In most trials the dose ranged between 3 and 9 million units daily or three times a week.6,7 The risk of IFNα related retinopathy and splinter haemorrhages is increased at high doses.8 Moreover, relatively low doses were found to be as effective as the high IFNα doses, with fewer side effects.9 Therefore, we started the treatment with 5 million units three times a week. The duration of IFNα treatment is also controversial. Most studies have used the drug for a 3–6 month course, although shorter and longer treatments have also been reported.10 Recurrences have been reported in a number of patients when treatment was stopped.11,12 Accordingly, we continued the IFNα treatment with dose tapering and later increasing the intervals between doses. Evaluation of response to any treatment including IFNα is complicated and is usually based on the clinical features of BD. Therefore some of the criteria mentioned in the manuscript remain subjective. However, the results of this open study suggest that IFNα may be an effective, safe, and well tolerated therapeutic alternative in BD where sight or life is threatened. Controlled studies are needed to elucidate its possible role as a first line agent in BD and its optimal therapeutic dosage and duration of treatment.

REFERENCES
Serum prolactin stress values in patients with systemic lupus erythematosus

C Dostál, L Moszkorzová, L Musilová, Z Lacinová, J Marek and J Zvárová

doi: 10.1136/ard.62.5.487

Updated information and services can be found at:
http://ard.bmj.com/content/62/5/487

**References**

This article cites 7 articles, 2 of which you can access for free at:
http://ard.bmj.com/content/62/5/487#BIBL

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/